Clinical Trial Update: HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HRS-4642 with gemcitabine, nab-paclitaxel, and adebrelimab for neoadjuvant and adjuvant pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Gemcitabine (Gemcitabine)
• HRS-4642
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Ruijin Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING